2016
DOI: 10.4081/oncol.2016.320
|View full text |Cite
|
Sign up to set email alerts
|

Urinary bladder cancer: biomarkers and target therapy, new era for more attention

Abstract: Currently, bladder cancer (BCa) evaluation depends mainly on traditional clinicopathological parameters encompassing tumor stage and grade, which will not reflect the behavior of the disease. Diverse molecular alterations are responsible for the heterogeneous course. The differences in molecular pathogenesis between non-invasive BCa and invasive BCa have been recognized. Molecular biomarkers are promising to predict progression and survival. The management of advanced BCa remains somewhat primitive in comparis… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
26
0
1

Year Published

2017
2017
2021
2021

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 28 publications
(27 citation statements)
references
References 63 publications
0
26
0
1
Order By: Relevance
“…Even the most effective neoadjuvant chemotherapy produces favorable responses in only about 25% of BC patients . Few advances in the treatment of BC have been found in recent decades . Therefore, a novel effective treatment strategy is urgently required in the management of BC.…”
Section: Introductionmentioning
confidence: 99%
“…Even the most effective neoadjuvant chemotherapy produces favorable responses in only about 25% of BC patients . Few advances in the treatment of BC have been found in recent decades . Therefore, a novel effective treatment strategy is urgently required in the management of BC.…”
Section: Introductionmentioning
confidence: 99%
“…The holistic vision of cancer, including histopathology, omics, cancer microenvironment, and interactions with the immune system, could determine a more accurate prognosis [25,26]. Despite attempts to improve the predictive capacity of the tumor-node-metastasis (TNM) staging system [2,27], or to introduce mutational, transcriptional, and epigenetic analyses [26], significant variations in the outcome of patients with similar BC status still remain, underling the need for new clinically relevant…”
Section: Discussionmentioning
confidence: 99%
“…81% of patients demonstrated progressive disease and the median survival time was 3 months (Petrylak et al, 2010). Almost all anti-angiogenic agents as sunitinib, pazopanib, aflibercept and ramucirumab have been evaluated in multiple settings in UC, without clear clinical benefit (Mohammed et al, 2016). These trials failed mostly due to lack of biomarkers.…”
Section: Treatment Of Bladder Cancermentioning
confidence: 99%